MetaVia Inc. (MTVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MetaVia Inc. (MTVA) has a cash flow conversion efficiency ratio of -0.469x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($9.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MetaVia Inc. net asset quality index to measure how much of total assets are equity-financed.
MetaVia Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how MetaVia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore cash flow to debt ratio of MetaVia Inc. to assess how comfortably operating cash covers total debt obligations.
MetaVia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MetaVia Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLG Corp Ltd
AU:GLE
|
0.125x |
|
TG-17, Inc. Common Stock
NASDAQ:OBAI
|
0.161x |
|
SGF Capital Public Company Limited
BK:SGF
|
0.068x |
|
reAlpha Tech Corp. Common Stock
NASDAQ:AIRE
|
-0.335x |
|
Mount Burgess Mining NL
AU:MTB
|
0.097x |
|
EAT WELL INVESTMENT GROUP
F:6BC0
|
N/A |
|
Bell Copper Corp
V:BCU
|
0.031x |
|
Raiden Resources Ltd
AU:RDN
|
-0.066x |
Annual Cash Flow Conversion Efficiency for MetaVia Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of MetaVia Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MetaVia Inc. (MTVA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.33 Million | $-15.70 Million | -2.944x | +5.50% |
| 2024-12-31 | $7.93 Million | $-24.71 Million | -3.116x | -381.38% |
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -152.65% |
| 2018-12-31 | $-13.29 Million | $-14.45 Million | 1.088x | +115.93% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more